-
Uncategorized2 days agoCrystalys doses first patients in Phase II gout trial
Crystalys Therapeutics has dosed the first patients in a Phase II trial evaluating a treatment for difficult-to-treat gout. The trial will evaluate dotinurad, a next-generation, once daily, oral URAT1...
-
Uncategorized2 days ago
Four years and 219 lost companies later, biotech still has a cash problem
Four years and 219 lost companies later, biotech still has a cash problem
-
Uncategorized2 days agoSTAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where...
-
Uncategorized2 days ago
Merck, Gilead serve ‘sweet and sour’ spread after HIV win, cancer stumble
Merck, Gilead serve ‘sweet and sour’ spread after HIV win, cancer stumble
-
Uncategorized2 days agoSTAT+: NIH staffers published a letter of dissent a year ago. They feel it’s been ignored
Last June, hundreds of staffers at the National Institutes of Health broke rank in an unprecedented move and published an open letter of dissent to agency...
-
Uncategorized2 days ago
ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data
AstraZeneca is pushing its small molecule GLP-1 drug to Phase 3 development for weight control, diabetes and other cardiometabolic conditions despite the asset failing to best...
-
Uncategorized2 days agoSTAT+: What’s changed since the last major Ebola outbreak
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. After much deliberation, STAT has made...
-
Uncategorized2 days ago
GSK pays $10.6B for cancer biotech Nuvalent in industry’s second-biggest buy of the year
Nuvalent Bio is GSK’s third big-ticket purchase this year, after the pharma dropped $2.2 billion in January for RAPT Therapeutics and $950 million in February for...
-
Uncategorized2 days ago
ADA: Lilly bests Novo again, takes GLP-1 pill Foundayo to FDA for diabetes approval
Newly approved weight loss pill Foundayo reduced blood sugar more than Novo Nordisk’s semaglutide and other comparators in multiple Phase 3 type 2 diabetes trials. Eli...
-
Uncategorized3 days agoOpinion: Why STAT is sticking with ‘health care’ as two words
After the Associated Press Stylebook made the startling decision in April to shift from “health care” to “healthcare,” it set off a fierce debate not only...
An obesity drug deep-dive, and peptides move mainstream
RFK Jr. claims his calendar is publicly available. We’ve been trying to get it for a year
